|
1
|
Villa D, Jiang A, Crosbie N, Rule S, McCulloch R, Visco C, Buege MJ, Kumar A, Bond D, Paludo J, Maurer MJ, Thanarajasingam G, Baech J, El‐Galaly T, Kugathasan L, Gerrie AS, Lewis D. TIME TO SECOND LINE BRUTON TYROSINE KINASE THERAPY AND AGE AT ITS INITIATION ARE STRONGLY ASSOCIATED WITH SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FIRST RELAPSE OF MANTLE CELL LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.59_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- D. Villa
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - A. Jiang
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - N. Crosbie
- University Hospitals Plymouth NHS Trust Haematology Plymouth UK
| | - S. Rule
- University Hospitals Plymouth NHS Trust Haematology Plymouth UK
| | - R. McCulloch
- University Hospitals Plymouth NHS Trust Haematology Plymouth UK
| | - C. Visco
- University of Verona Hematology Verona Italy
| | - M. J. Buege
- Memorial Sloan Kettering Cancer Center Clinical Pharmacy, Lymphoma New York USA
| | - A. Kumar
- Memorial Sloan Kettering Cancer Center Division of Hematologic Malignancies New York USA
| | - D. Bond
- The Ohio State University Hematology Columbus USA
| | - J. Paludo
- Mayo Clinic Hematology Rochester USA
| | - M. J. Maurer
- Mayo Clinic Division of Clinical Trials and Biostatistics Rochester USA
| | | | - J. Baech
- Aalborg University Hospital Haematology Aalborg Denmark
| | - T. El‐Galaly
- Aalborg University Hospital Haematology Aalborg Denmark
| | - L. Kugathasan
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - A. S. Gerrie
- BC Cancer, Centre for Lymphoid Cancer Vancouver Canada
| | - D. Lewis
- University Hospitals Plymouth NHS Trust Haematology Plymouth UK
| |
Collapse
|
|
2
|
Ferreri AJM, Steffanoni S, Calimeri T, Laurenge A, Fox CP, Soussain C, Grommes C, Sassone MC, Touat M, Boot J, Crosbie N, Chaganti S, Dietrich J, Alencar A, Itchaki G, Hoang Xuan K, Batchelor T, Cwynarski K. SARS‐COV‐2 INFECTION IN 50 PATIENTS WITH PRIMARY CNS LYMPHOMA: PRESENTATION, EFFECTS ON TUMOR TREATMENT AND OUTCOME IN A SERIES OF THE INTERNATIONAL PCNSL COLLABORATIVE GROUP. Hematol Oncol 2021. [DOI: 10.1002/hon.68_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - S. Steffanoni
- IRCCS San Raffaele Lymphoma Unit Hematology Milan Italy
| | - T. Calimeri
- IRCCS San Raffaele Lymphoma Unit Hematology Milan Italy
| | - A. Laurenge
- Hôpitaux Universitaires La Pitié Salpêtrière Service de Neurologie 2‐Mazarin Paris France
| | - C. P. Fox
- University Hospitals NHS Trust hematology Nottingham UK
| | - C. Soussain
- Hôpital René Huguenin‐Institut Curie Saint‐Cloud Hematology Paris France
| | - C. Grommes
- Memorial Sloan Kettering Cancer Center Department of Neurology New York USA
| | - M. C. Sassone
- IRCCS San Raffaele Lymphoma Unit Hematology Milan Italy
| | - M. Touat
- Hôpitaux Universitaires La Pitié Salpêtrière Service de Neurologie 2‐Mazarin Paris France
| | - J. Boot
- Barking Havering and Redbridge University Hospitals NHS Trust Hematology London UK
| | - N. Crosbie
- Derriford Hospital Hematology Plymouth UK
| | - S. Chaganti
- Queen Elizabeth Hospital Haematology Birmingham UK
| | - J. Dietrich
- Massachusetts General Hospital Cancer Center Neuro‐Oncology Boston USA
| | - A. Alencar
- University of Miami/Sylvester Comprehensive Cancer Center Department of Hematology and Oncology Miami USA
| | - G. Itchaki
- Davidoff Cancer Center Rabin Medical Center Hematology Petah‐Tikva Israel
| | - K. Hoang Xuan
- Hôpitaux Universitaires La Pitié Salpêtrière Service de Neurologie 2‐Mazarin Paris France
| | - T. Batchelor
- Brigham and Women’s Hospital Neurology, Boston, Massachusetts USA 13 University College London Hospital Haematology London UK
| | | |
Collapse
|
|
3
|
Korfi K, Araf S, Bewicke-Copley F, Kumar E, Cummin T, Ashton-Key M, Barrans S, Van Hoppe S, Burton C, Elshiekh M, Rule S, Crosbie N, Clear A, Calaminici M, Menon G, Sha C, Bentley M, Nagano A, Davies A, Painter D, Smith A, Okosun J, Gribben J, Naresh K, Westhead D, Wang J, Johnson P, Fitzgibbon J. LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.100_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- K. Korfi
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - S. Araf
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - F. Bewicke-Copley
- Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
| | - E. Kumar
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - T. Cummin
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - M. Ashton-Key
- Cellular Pathology; University Hospital Southampton NHS Foundation Trust; Southampton United Kingdom
| | - S. Barrans
- HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
| | - S. Van Hoppe
- HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
| | - C. Burton
- HMDS; Leeds Teaching Hospitals NHS Trust; Leeds United Kingdom
| | - M. Elshiekh
- Cellular & Molecular Pathology; Imperial College NHS Trust & Imperial College London; London United Kingdom
| | - S. Rule
- Department of Haematology; Derriford Hospital, University of Plymouth; Plymouth United Kingdom
| | - N. Crosbie
- Department of Haematology; University Hospitals Plymouth NHS Trust; Plymouth United Kingdom
| | - A. Clear
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - M. Calaminici
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - G. Menon
- Haemato-Oncology Diagnostic Service; Liverpool Clinical Laboratories; Liverpool United Kingdom
| | - C. Sha
- School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
| | - M. Bentley
- School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
| | - A. Nagano
- Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
| | - A. Davies
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - D. Painter
- Epidemiology and Cancer Statistics Group; University of York; York United Kingdom
| | - A. Smith
- Epidemiology and Cancer Statistics Group; University of York; York United Kingdom
| | - J. Okosun
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - J. Gribben
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| | - K.N. Naresh
- Cellular & Molecular Pathology; Imperial College NHS Trust & Imperial College London; London United Kingdom
| | - D. Westhead
- School of Molecular and Cellular Biology; University of Leeds; Leeds United Kingdom
| | - J. Wang
- Centre for Molecular Oncology; Barts Cancer Institute; London United Kingdom
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton United Kingdom
| | - J. Fitzgibbon
- Centre for Haemato-Oncology; Barts Cancer Institute; London United Kingdom
| |
Collapse
|